Börse:
14,203€
5,20%
Echtzeit-Aktienkurs Omeros Corp
Bid:
14,085€
Ask:
14,320€
| Allgemeine Informationen | ||
|---|---|---|
| Börsenwert: | 696,09 Mio. EUR (49,01 Mio. x 14,203€) | |
| Website: | - | |
| Sektor: | Medizin / Biotechnologie | |
| News-Radar | |
|---|---|
| dpa-AFX Pro - | Newsbot - |
| dpa-AFX - | Reuters - |
| 2015 | 2016 | 2017 | 2018 | |
|---|---|---|---|---|
| KUV | 39,99 | 14,95 | 10,56 | 23,31 |
| KGV | - | - | - | - |
| Div. Rend. | - | - | - | - |
Echtzeit-Chart der Omeros Corp Aktie
Börsenkurse Omeros Corp
| Lang & Schwarz | 14,165€ | 844 | 14,280€ | 844 | 14,223€ | 2,76% |
| Euro Indikation | 14,085€ | 0 | 14,320€ | 0 | 14,203€ | 5,20% |
| Tradegate | 14,160€ | 353 | 14,250€ | 350 | 14,205€ | 2,69% |
| Börse Stuttgart | 14,085€ | 0 | 14,320€ | 0 | 14,203€ | 3,67% |
| Dollar Indikation | 15,742$ | 0 | 15,983$ | 0 | 15,863$ | 3,00% |
Fundamentaldaten der Omeros Corp Aktie
Aktuelle Geschäftsentwicklung
Sie benötigen die TraderFox Börsensoftware, um die aktuelle Geschäftsentwicklung einsehen zu können.
Income Statement: 10-Year-Summary
| Datum | Umsatz | EBIT | Gewinn | EPS | Dividende | KGV | KUV |
|---|---|---|---|---|---|---|---|
| 2018 | 29,87 Mio. | -139,69 Mio. | -126,76 Mio. | -2,61 | 0,00% | - | 23,31 |
| 2017 | 64,83 Mio. | -53,48 Mio. | -53,48 Mio. | -1,17 | 0,00% | - | 10,56 |
| 2016 | 41,62 Mio. | -66,75 Mio. | -66,75 Mio. | -1,65 | 0,00% | - | 14,95 |
| 2015 | 13,51 Mio. | -75,10 Mio. | -75,10 Mio. | -2,00 | 0,00% | - | 39,99 |
| 2014 | 0,54 Mio. | -73,67 Mio. | -73,67 Mio. | -2,22 | 0,00% | - | 900,77 |
| 2013 | 1,60 Mio. | -39,80 Mio. | -39,80 Mio. | -1,39 | 0,00% | - | 269,49 |
| 2012 | 6,02 Mio. | -38,44 Mio. | -38,44 Mio. | -1,59 | 0,00% | - | 61,08 |
| 2011 | 4,52 Mio. | -28,55 Mio. | -28,55 Mio. | -1,29 | 0,00% | - | 70,42 |
| 2010 | 2,11 Mio. | -29,25 Mio. | -29,25 Mio. | -1,37 | 0,00% | - | 147,90 |
| 2009 | 1,44 Mio. | -21,09 Mio. | -21,09 Mio. | -2,92 | 0,00% | - | 209,36 |
Profil der Omeros Corp Aktie
Omeros Corp. operates as a biopharmaceutical company committed to discovering, developing, and commercializing small-molecule and protein therapeutics for large market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.
TraderFox GmbH:
Impressum & Datenschutz -
Allgemeine Geschäftsbedingungen